HCC827ER HGF(-). HCC827ER HGF(+). % cell viability. % cell viability. Drug concentration (μM). Drug concentration (μM). Supplementary Figure 1. The effect of 17-DMAG on the growth of lung cancer cells with Met amplification - PowerPoint PPT Presentation
Citation preview
Supplementary Figure 1. The effect of 17-DMAG on the growth of
lung cancer cells with Met amplificationTumor cells were
continuously treated with increasing concentrations of EGFR-TKI,
erlotinib, or 17-DMAG, with or without HGF (20 ng/ml), and cell
growth was determined after 72 hours by MTT assay. Data shown are
the representative of 3 independent experiments. Error bars
indicate SD of triplicate cultures.
Supplementary Figure 2. The effect of combined therapy with
17-DMAG and EGFR-TKI on the growth of lung cancer cells with
mutated EGFR Tumor cells were continuously treated with increasing
concentrations of EGFR-TKI, erlotinib (PC-9 and Ma-1/HGF),
CL-387,785 (H1975), or 17-DMAG, with or without HGF (20 ng/ml), and
cell growth was determined after 72 hours by MTT assay. Data shown
are the representative of 3 independent experiments. Error bars
indicate SD of triplicate cultures.
AnnexinVPIControl Erlotinib 17-DMAG HGFHGF+Erlotinib
HGF+17-DMAGMa-1Ma-1/VecMa-1/HGFSupplementary Figure 4. 17-DMAG
induces apoptosis even in the presence of HGF. Ma-1, Ma-1/Vec, and
Ma-1/HGF cells were incubated with HGF (20 ng/mL) and erlotinib
(0.3 mol/L) or 17-DMAG (0.3 mol/L) for 48 hour and washed twice
with PBS. The apoptotic cells were determined by Annexin V assays
according to the manufactors protocol. Values shown are percentage
of apoptotic cells. FL1-H and FL2-H, heights of fluorescence
intensity.
Supplementary Figure 5. The effect of combination treatment with
17-DMAG plus erlotinib to HGF-induced erlotinib resistance in vivo.
Ma-1 /Vec (A) or Ma-1/HGF (B) (5 106) cells were inoculated
subcutaneously into SCID mice on day 0. Mice received oral
erlotinib (20 mg/kg/d) and/or intraperitoneal 17-DMAG (10 mg/kg/d),
starting on day 7. Tumor size was measured twice a week and tumor
volumes were calculated as described in Materials and Methods.
Error bars indicate standard errors of 6tumors. C, macroscopic
appearances of representative tumors harvested on day 21.
123456781: Ma-1 Control2: Ma-1 Erlotinib3: Ma-1 17-DMAG4: Ma-1
Combination5: Ma-1/HGF Control6: Ma-1/HGF Erlotinib7: Ma-1/HGF
17-DMAG8: Ma-1/HGF CombinationCAB
